Expert Insights - 19th Annual International Ultmann Chicago Lymphoma Symposium
We were fortunate to have a multitude of the world’s experts in lymphoma speak at this year’s conference. The live audience was comprised of regional practicing oncologists, advanced nurse practitioners and physician assistants, residents, fellows, and the Chicago academic community that included five academic centers.
This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. This year’s conference was a 2-day live meeting to discuss recent updates in the care of patients with solid and hematologic malignancies.
After completing this activity, the participant should be better able to:
- Compare and contrast the latest approaches to the treatment of patients with indolent and aggressive forms of non-Hodgkin lymphoma;
- Evaluate current and emerging approaches to the treatment of patients with Hodgkin lymphoma;
- Assess the latest clinical trial data of current and emerging CAR T-cells and cellular therapy for patients with hematologic malignancies, including important safety and efficacy data;
- Discuss patient and disease-related factors that impact the selection and sequencing of therapy for patients with CLL;
- Develop strategies to utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma.
Elwood V. Jensen Professor of Medicine
Chief, Section of Hematology/Oncology
Director, Lymphoma Program
University of Chicago
Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Associate Director for Clinical Services, Rutger Cancer Institute of New Jersey
Director, Lymphoma Program, Division of Blood Disorders
Medical Director, Oncology Service Line, RWJBarnabas Health
Professor, Division of Hematology and Oncology
Medical College of Wisconsin
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and Bio Ascend LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.